PMID- 19483648
OWN - NLM
STAT- MEDLINE
DCOM- 20091005
LR  - 20220310
IS  - 1537-4513 (Electronic)
IS  - 1524-9557 (Linking)
VI  - 32
IP  - 6
DP  - 2009 Jul-Aug
TI  - Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through 
      crossreactivity with HM1.24.
PG  - 613-21
LID - 10.1097/CJI.0b013e3181a95198 [doi]
AB  - The Melan-A(aa26-35) (EAAGIGILTV) peptide is a human leukocyte antigen 
      (HLA)-A2-restricted T-cell epitope within the Melan-A/MART-1 tumor antigen 
      expressed on malignant melanoma cells. Melan-A and Melan-A analog (ELAGIGILTV, 
      Melan-A(aa26-35*A27L)) specific T-cells can be expanded reliably for 
      immunotherapeutic approaches in vitro. We studied the ability of Melan-A analog 
      (ELAGIGILTV, Melan-A(aa26-35*A27L)) specific T-cells to recognize the 
      HM1.24(aa22-30) (LLLGIGILV) peptide within the HM1.24 antigen presented by normal 
      and malignant plasma cells. Peripheral blood mononuclear cells from HLA-A2+ 
      healthy donors and HLA-A2+ multiple myeloma (MM) patients were stimulated with 
      Melan-A analog peptide-loaded autologous dendritic cells, and expanded in vitro. 
      T-cell activation was assessed by interferon-gamma specific enzyme-linked 
      immunosorbent spot and cytotoxicity by (51)Chromium-release-assays. The frequency 
      of Melan-A analog specific CD8+ T-cells was detected by using tetramers. Melan-A 
      analog specific T-cells from HLA-A2+ healthy donors and HLA-A2+ MM patients 
      showed a interferon-gamma secretion mediated by HM1.24(aa22-30) peptide-pulsed T2 
      cells and lysed the HLA-A2+ HM1.24+ U266 and XG-1 human myeloma derived 
      cell-lines as well as the B-lymphoblastoid cell-line IM-9. Melan-A analog 
      specific T-cells from MM patients specifically lysed autologous MM cells. The 
      current data demonstrate that Melan-A analog specific T-cells crossreact with 
      HM1.24(aa22-30). They might be a tool for the future use in immunotherapy against 
      MM.
FAU - Christensen, Olaf
AU  - Christensen O
AD  - Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany. 
      olaf.christensen@bayer.com
FAU - Lupu, Alaviana
AU  - Lupu A
FAU - Schmidt, Stefanie
AU  - Schmidt S
FAU - Condomines, Maud
AU  - Condomines M
FAU - Belle, Sebastian
AU  - Belle S
FAU - Maier, Ariane
AU  - Maier A
FAU - Hose, Dirk
AU  - Hose D
FAU - Neuber, Brigitte
AU  - Neuber B
FAU - Moos, Marion
AU  - Moos M
FAU - Kleist, Christian
AU  - Kleist C
FAU - Terness, Peter
AU  - Terness P
FAU - Ho, Anthony D
AU  - Ho AD
FAU - Goldschmidt, Hartmut
AU  - Goldschmidt H
FAU - Klein, Bernard
AU  - Klein B
FAU - Hundemer, Michael
AU  - Hundemer M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Immunother
JT  - Journal of immunotherapy (Hagerstown, Md. : 1997)
JID - 9706083
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (BST2 protein, human)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (GPI-Linked Proteins)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (MART-1 Antigen)
RN  - 0 (MLANA protein, human)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Peptides)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Antigens, CD/*immunology
MH  - Antigens, Neoplasm/*immunology
MH  - CD8-Positive T-Lymphocytes/*immunology/transplantation
MH  - Cancer Vaccines/immunology
MH  - Cell Line, Tumor
MH  - Cross Reactions/immunology
MH  - Cytotoxicity, Immunologic/immunology
MH  - Dendritic Cells/*immunology
MH  - Epitopes, T-Lymphocyte/immunology
MH  - Female
MH  - GPI-Linked Proteins
MH  - HLA-A2 Antigen/immunology
MH  - Humans
MH  - *Immunotherapy, Adoptive
MH  - Interferon-gamma/biosynthesis/immunology
MH  - MART-1 Antigen
MH  - Male
MH  - Membrane Glycoproteins/*immunology
MH  - Multiple Myeloma/*immunology/therapy
MH  - Neoplasm Proteins/*immunology
MH  - Peptides/immunology
EDAT- 2009/06/02 09:00
MHDA- 2009/10/06 06:00
CRDT- 2009/06/02 09:00
PHST- 2009/06/02 09:00 [entrez]
PHST- 2009/06/02 09:00 [pubmed]
PHST- 2009/10/06 06:00 [medline]
AID - 10.1097/CJI.0b013e3181a95198 [doi]
PST - ppublish
SO  - J Immunother. 2009 Jul-Aug;32(6):613-21. doi: 10.1097/CJI.0b013e3181a95198.